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Differences in PfEMP1s recognized 
by antibodies from patients with uncomplicated 
or severe malaria
Michael F. Duffy1*, Rintis Noviyanti2, Takafumi Tsuboi3, Zhi‑Ping Feng4,5, Leily Trianty2, Boni F. Sebayang2, 
Eizo Takashima3, Fransisca Sumardy1, Daniel A. Lampah6, Louise Turner7, Thomas Lavstsen7, Freya J. I. Fowkes8, 
Peter Siba9, Stephen J. Rogerson1, Thor G. Theander7, Jutta Marfurt10, Ric N. Price10,11, Nicholas M. Anstey10, 
Graham V. Brown12 and Anthony T. Papenfuss4,5,13,14
Abstract 
Background: Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) variants are encoded by var genes 
and mediate pathogenic cytoadhesion and antigenic variation in malaria. PfEMP1s can be broadly divided into 
three principal groups (A, B and C) and they contain conserved arrangements of functional domains called domain 
cassettes. Despite their tremendous diversity there is compelling evidence that a restricted subset of PfEMP1s is 
expressed in severe disease. In this study antibodies from patients with severe and uncomplicated malaria were 
compared for differences in reactivity with a range of PfEMP1s to determine whether antibodies to particular PfEMP1 
domains were associated with severe or uncomplicated malaria.
Methods: Parts of expressed var genes in a severe malaria patient were identified by RNAseq and several of these 
partial PfEMP1 domains were expressed together with others from laboratory isolates. Antibodies from Papuan 
patients to these parts of multiple PfEMP1 proteins were measured.
Results: Patients with uncomplicated malaria were more likely to have antibodies that recognized PfEMP1 of Group 
C type and recognized a broader repertoire of group A and B PfEMP1s than patients with severe malaria.
Conclusion: These data suggest that exposure to a broad range of group A and B PfEMP1s is associated with protec‑
tion from severe disease in Papua, Indonesia.
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Background
PfEMP1 is the immunodominant antigen of the malaria 
parasite Plasmodium falciparum expressed on the sur-
face of the infected erythrocyte (IE). Adherence of this 
molecule to host receptors expressed on endothelial 
cells, uninfected erythrocytes and placental syncytio-
trophoblasts facilitates sequestration of IE in vascular tis-
sues, avoiding destruction in the spleen [1–3]. PfEMP1 
molecules are encoded by the var multigene family [1–3]. 
Individual parasites have approximately 60 var gene vari-
ants and switching between single, transcribed var genes 
leads to changes in cytoadhesive phenotype as well as 
clonal antigenic variation and immune escape. var gene 
repertoires differ among isolates [4] and immunity to 
malaria is dependent on acquisition of antibodies to a 
range of PfEMP1 variants [5–8]. Immunity to both cer-
ebral malaria [9] and non-cerebral, severe malaria [10] is 
acquired much more rapidly than immunity to uncompli-
cated malaria. Parasites that cause severe disease appear 
to express a conserved subset of variant antigens that are 
encountered earlier in life and that are thus more widely 
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recognized by sera from semi-immune children than par-
asites causing uncomplicated disease [11, 12].
PfEMP1s contain combinations of Duffy binding-like 
domains (DBLα, β, γ, δ, ε, ζ and x) and cysteine rich inter-
domain regions (CIDRα, β, γ and δ) [13]. Some DBL 
and CIDR domain subtypes mediate adhesion to differ-
ent host receptors (reviewed in [14, 15]), and some are 
organized in semi-conserved domain cassettes (DC) that 
are present in most parasites [4]. var genes are also clas-
sified using their upstream sequence into groups A, B, 
C [16, 17] which comprise 20, 60 and 20 % respectively 
of the var gene repertoire [4]; the unique var gene called 
var2csa has a different upstream sequence (ups E) and is 
only involved in malaria during pregnancy [18].
The expression of particular subtypes of DBLα domains 
in severe malaria suggests severe disease may be pref-
erentially caused by a restricted subset of var genes [19, 
20]. Increased expression of group A and B var genes has 
been associated with clinical, but not specifically severe 
malaria in Papua New Guinea (PNG) [21, 22] and with 
severe malaria in Africa [23]. Cerebral malaria in Africa 
was associated with increased expression of group A [20, 
24, 25] or group B [26] var genes.
Consistent with its having a role in severe malaria, 
PfEMP1s encoded by group A and B var genes appear to 
be widely expressed by parasites that infect non- or semi-
immune individuals. Antibodies from older children 
preferentially recognized PfEMP1s encoded by Group A 
var genes, indicating previous exposure [27]. Group A 
and B var genes dominated infection of a naive individual 
[28], and more individuals develop antibodies to group A 
PfEMP1s than group B or C, and do so at a younger age 
[29].
Group A and B var genes also encode adhesion pheno-
types associated with severe disease. In Africa the adhe-
sion phenotype of rosetting is associated with severe 
malaria [14] and increased expression of group A var 
genes [19, 21, 25]. Some group A and B PfEMP1s can 
bind to intercellular adhesion molecule 1 (ICAM-1) [30, 
31], and ICAM-1 expression was up-regulated in brain 
endothelium and co-localized with sequestered IEs in 
cerebral malaria patients [32]. IE adhesion to ICAM-1 
has variously been associated with cerebral malaria [33], 
clinical but not severe malaria [34] or inversely correlated 
with severe disease [35].
Another phenotype associated with severe disease is 
adhesion to endothelial protein C receptor, EPCR [36, 
37]. Parasite isolates from African children with severe 
malaria bound EPCR and expressed DC8 or DC13 var 
genes [36, 38]. DC8 and DC13 PfEMP1s are primarily 
group B and A, respectively [4], and contain members of 
the subset of CIDRα1 domain types, which bind EPCR 
[36, 37]. Sera from African children with uncomplicated 
malaria recognize PfEMP1s containing DC8 and DC13 at 
higher levels than PfEMP1s without DC8 or 13, but it is 
unclear whether severe malaria specifically induces anti-
bodies to DC8 and DC13 [39, 40].
DC5 PfEMP1s, which are nearly all group A, are rec-
ognized by sera from semi-immune children in a similar 
manner to other severe malaria associated isolates [27], 
and DC5 expression increased markedly during infec-
tion of a naive volunteer [41]. African children acquired 
antibodies to DC5 more rapidly than to other PfEMP1 
domains which is consistent with widespread expres-
sion of DC5 in non-immune individuals [29]. Antibodies 
reactive with DC5 also correlated with protection from 
malaria episodes [42]; however, the evidence directly 
linking DC5 PfEMP1 expression and adhesion phe-
notype to severe malaria is less clear. High levels of 
DC5 sequence expression have been detected in severe 
malaria, but only together with expression of either DC8 
or 13 sequences [38] and it is conceivable that these 
DC5 and DC8 or DC13 sequences were present on the 
same var genes. DC5 PfEMP1s bind platelet-endothelial 
cell adhesion molecule 1 (PECAM1) [43] and IE adhe-
sion to PECAM1 has been implicated in cerebral malaria 
[44, 45]. However, IE adhesion to PECAM1 is also com-
monly found in samples from patients with uncompli-
cated malaria [46] and DC5 PfEMP1s were not expressed 
by parasites selected for adhesion to brain endothelium 
[39, 40]. A minority of var genes containing DC5 do 
encode EPCR-binding CIDRα1.5 domains although these 
domains are not part of the DC5 cassette [4].
Thus several promising candidates have emerged 
as members of the restricted population of PfEMP1s 
responsible for severe malaria, but the relative contribu-
tions of group A and B, and of DCs 8, 13 and 5 remain 
unclear. In particular very little is known about PfEMP1s 
in severe disease in the Asia Pacific region. Determining 
whether conserved PfEMP1sequences elicit protection 
from severe malaria disease globally is a priority for vac-
cine research. In this study plasmas from Papuan patients 
with severe or uncomplicated malaria were analysed for 
their reactivity with PfEMP1 polypeptides representa-
tive of the different groups and DCs including several 
expressed by parasites causing cerebral malaria.
Methods
Patient samples
Two ml of venous blood was collected from a 5-year old 
female patient with cerebral malaria in PNG. The IEs 
were separated from white blood cells by Plasmodipur 
column filtration (Europroxima) as per the manufac-
turer’s instructions. The IEs were lysed in TRIzol® (Life 
Technologies), incubated at 37  °C for 5  min and then 
stored at −80  °C. Venous samples were collected from 
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patients with severe (n = 28) and uncomplicated (n = 35) 
malaria attending a healthcare facility in Timika, Papua 
Province, Indonesia. Plasma was separated from blood by 
centrifugation and stored at −20 °C. This area has unsta-
ble malaria transmission with estimated annual parasite 
incidence of 450 per 1000 population and symptomatic 
illness in all ages [47]. Severe malaria was defined as 
peripheral parasitaemia with at least one modified World 
Health Organization (WHO) criterion of severity [48]. 
Twenty-six of the 28 patients with severe malaria had 
parasitemias greater than 1000/μL, which is a previously-
derived threshold that predicts clinical disease in north-
ern Papua [49]. Thus incidental parasitemia is unlikely in 
these 26 severe malaria patients but cannot be excluded 
in the two severe malaria patients with parasitemias less 
than 1000/μl.
Ethics
Informed consent was provided by all participants. The 
study was approved in Indonesia by the Eijkman Insti-
tute Research Ethics Commission (project number 46), 
in Australia by the Melbourne Health Human Research 
Ethics Committee (project number 2010.284) and 
Human Research Ethics Committee of the NT Depart-
ment of Health & Families and Menzies School of Health 
Research, Darwin, Australia (HREC 2010–1396), and 
in PNG by the Government of PNG Medical Research 
Advisory Committee (MRAC no. 11.12).
RNA extraction and RNAseq
Erythrocytes in TRIzol® were thawed at 37  °C, chlo-
roform (1/5th of the TRIzol® volume) was added and 
vortexed 15 s, the solution was then subjected to centrif-
ugation at 12,000×g for 30 min at 4 °C and the aqueous 
supernatant was aspirated and mixed with an equal vol-
ume of 70  % ethanol in RNase free water. This solution 
was then directly applied to RNeasy mini columns (QIA-
GEN), and RNA purification was performed with on-
column DNasing as per the manufacturer’s instructions. 
Eluted RNA was oligo dT purified and used to generate a 
65 bp paired end RNAseq library using the standard Illu-
mina protocol. The library was sequenced on an Illumina 
GAII at Geneworks (Adelaide).
Alignments were performed using Subreads [50]. 
Reads were first aligned to the 399 full length var genes 
that were previously described in seven P. falciparum 
isolates [4] and mapped reads were extracted. Reads 
were also aligned to the 3D7 P. falciparum genome and 
unmapped reads were extracted to include any var that 
may have been missed. The reads that mapped to var 
genes and the reads that did not map to the 3D7 genome 
were then merged, digitally normalized using khmer [51], 
and assembled using Oases [52]. Assembled transcripts 
were subjected to a second round of de novo assembly 
using Cap3 [53] to assemble contigs and extract consen-
sus sequences from the contigs. Contigs were aligned to 
the domains from the 399 var genes with BLAST (ver-
sion 2.2.25). The transcript abundance was determined 
by aligning the reads again to the assembled transcripts.
Protein expression
Proteins for Luminex assays were expressed in bacu-
lovirus-transfected insect cells as previously described 
[54]. Proteins analysed by Luminex were IT4var02 
protein 1 DBLγ12DBLδ5CIDRβ3DBLβ9, PF11_0008 
DBLδ5CIDRβ4, IT4var02 protein 2 DBLδ5CIDRβ3, 
HB3var05 DC16 DBLα1.6CIDRδ1, PFI1820w var3 
DBLα1.3 DBLε8, PFD0020c DBLβ12 DBLγ6, IT4var20 
DBLα2C IDRα1.1DBLβ12DBLγ6DBLδ1C IDRβ1, 
PF11_0007 DBLα0.15CIDRα3.2DBLδ1CIDRβ1, 
PFL0020w DBLγ14DBLζ5DBLε4, IT4var13 DC 9 DBLα0.3
CIDRα5DBLβ5DBLδ9CIDRγ9DBLγ11DBLζ4.
PfEMP1 domains identified by RNAseq as expressed by 
the parasites infecting the PNG CM patient were ampli-
fied from gDNA purified from the patient’s blood for 
use as ELISA antigens. The sequences were then cloned 
into the plasmid pEU-E01H-N1 (encoding an N terminal 
His-tagged protein; CellFree Sciences Matsuyama, Japan) 
[55] and expressed in the wheat germ cell-free expression 
system (CellFree Sciences) and purified on Ni-nitrilotri-
acetic acid agarose columns (Qiagen, Valencia, CA) as 
previously described [55, 56].
Antigens used for the ELISA included proteins one to 
seven that were encoded by var gene sequences tran-
scribed by parasites infecting the cerebral malaria patient 
from PNG. Proteins 1 and 3 were encoded by 352  bp 
and 123 bp fragments of a contig with homology to the 
DC5 DBLβ7_D8 of Dd2var4 (ranked 33rd by transcript 
abundance) (Table 1). Protein 2 was encoded by a 861 bp 
orthologue of DC5 DBLδ5_D6_Dd2var4 that incor-
porated two contigs that were ranked 4th and 9th by 
abundance (Table 1). Protein 4 was encoded by a 697 bp 
fragment of a contig with homology to a DC8 DBLγ6_
D3_Dd2var47 (ranked 5th by abundance). Protein 5 was 
encoded by a 186 bp fragment with homology to DBLγ10 
of raj116 and was ranked 34th by abundance. Protein 6 
was encoded by a 425  bp contig that incorporated two 
non-overlapping contigs with homology to NTSB3_
DBLα0.11 of igh_var31 and DBLα0.15 of raj116_var34 
(ranked respectively14th and 21st by abundance). Protein 
7 was a 142  bp cloned orthologue of DBLδ1_D4_PFC-
LIN_var24 (ranked 96th by abundance).
Proteins 1, 2 and 3 were most closely related to the 
DC5 domain var gene Dd2var4. This gene has group 
A-like coding features, e.g. head structure and ATS, and 
is the only DC5 with a group B-like upstream sequence, 
Page 4 of 12Duffy et al. Malar J  (2016) 15:258 
Table 1 var sequences transcribed by parasites infecting a Papua New Guinean cerebral malaria patient
var Homologsa, b Notes RPKc Contig  
bp
Homology  
bp
E value % Identity
CIDRα2.4_D3_MAL7P1.55 7384 425 131 5.44E−34 84
DBLδ1_D4_ighvar31_CIDRγ9_
D5_ighvar35
5174 1553 133, 410 2.52E−32, 1E−100 82.7, 79
DBLδ9_D5_PFCLINvar74 4369 583 303 1.05E−44 76.2
DBLδ5_D6_Dd2var4 DC5 ELISA protein 2 4227 273 219 1.19E−52 80.4
DBLγ6_D3_DD2var47–DBLγ2_
D5_DD2var42
DC8 ELISA protein 4 4130 1807 190, 488 2.57E−58, 6.86E−148 86.3, 85
DBLβ6_D5_igh_var27 3562 395 258 3.17E−68 81.8
DBLε1_D6_PFCLINvar76 var1csa 3340 1025 429 0 100
CIDRα3.1_D3_DD2var50 2973 550 86.1 3.24E−57 86.1
DBLδ5_D6_Dd2var4 DC5 ELISA protein 2 2891 156 123 7.29E−46 92.7
CIDRβ1_D8_HB3var1 2814 650 161 7.44E−41 82.6
CIDRα3.1 pf08–0106–DBLδ5_
D5_igh_var30
2302 883 167, 310 1.51E−38, 7.32E−68 85.6, 80.6
DBLγ15_D5_PFCLINvar76 
(var1csa)
2199 246 230 2.56E−117 100
DBLγ17_D4_DD2var43–DBLδ5_
D5_HB3var2
DC5 2153 626 192, 250 4.51E−56, 4.23E−31 87.5, 73.6
NTSB3_D1_igh_var31–DBLα0.11_
D2_AAB60251
ELISA protein 6 2085 189 93, 80 1.03E−19, 1.03E−19 81.7, 85
DBLγ10_D5_HB3var34 DC17,21,22 1994 344 193 2.94E−74 91.7
CIDRβ1_D7_raj116_var11 DC8 1980 606 408 1.98E−60 73.8
DBLβ1_D4_igh_var19 DC8 1935 402 344 1.29E−98 83.7
DBLδ1_D4_HB3var50 1911 302 229 3.32E−60 82.1
DBLδ1_D4_IT4var39 1894 216 203 2.31E−41 76.4
DBLβ6_D4_igh_var9 1883 437 251 3.1E−75 85.3
DBLα0.15_D2_raj116_var34 ELISA protein 6 1871 132 125 6.84E−39 87.2
DBLδ1_D4_IT4var46–DBLγ4_
D5_raj116_var11
1867 1461 115, 258 4.57E−35, 3.5E−106 87.8, 84.1
DBLα0.1_D2_HB3var30 1846 338 215 5.37E−43 82.8
DBLγ6_D5_IT4var32b DC8 1833 307 178 1.45E−49 83.7
DBLγ13_D5_HB3var21 1822 828 402 1.09E−114 90.7
CIDRβ4_dd2var22–DBLβ3_D4_
HB3var3
DC5‑multi domain contig 1819 1152 707, 339 3.35E−86, 1.34E−59 70.9, 75.2
CIDRα2.9_D3_raj116_var14 –
DBLδ1_D6_IT4var32b
1741 534 43, 196 1.83E−15, 9.49E−32 100, 76
DBLα0.19_D2_Itvar66‑CIDRα2.4_
D3_raj116_var29
1729 410 96, 279 3.33E−36, 2.73E−56 93.8, 79.2
DBLδ1_D4_igh_var20 1724 480 237 5.43E−57 79.7
DBLδ1_D4_IT4var47 1714 263 172 3.28E−46 83.7
DBLδ1_D4_igh_var18 1696 289 227 2.78E−48 82.8
DBLδ1_D4_PFD1005c 1649 191 191 5.39E−36 76.9
DBLβ7_D8_Dd2var4 DC5 ELISA proteins 1 & 3 1644 859 793 1.46E−152 78.6
DBLγ10_D4_PFCLINvar71 ELISA protein 5 1587 511 204 2.3E−71 89.2
DBLβ5_D4_IT4var16‑DBLδ1_D4_
raj116_var32
1579 447 135, 62 5.743E−53, 1.11E−17 93.3, 90.3
DBLδ1_D4_raj116_var29 1573 309 297 2.3E−43 73.4
DBLβ12_D4_raj116_var11–
DBLγ11_D4_raj116_var17
1534 712 215, 178 7.05E−47, 1.45E−36 79.5, 80.3
DBLβ11_D4_IT4var35–DBLγ3_
D7_HB3var4
1520 931 163, 131 3.27E−65, 3.5E−33 93.3, 83.2
DBLε3_D8_raj116_var29 1508 179 60 3.63E−25 100
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the other 11 all being group A [4]. Therefore, proteins 1, 2 
and 3 were classified as group A for all subsequent analy-
ses. These PNG derived proteins were supplemented by 
domains from HB3, 3D7 and ItG parasites that included 
two DBLδ domains from group C PfEMP1s, a DC8 
CIDRα1.1, a DC13 CIDRα1.4 and a CIDRα3.1 (Fig. 2b).
Serology
The Luminex assay was performed as previously 
described [54]. For each protein an eleven point stand-
ard curve was made using two-fold dilutions of pooled 
positive plasma starting with 1/40, which was assigned 
an arbitrary value of 1000 relative units (RU). Plasmas 
were diluted in 0.02 % Tween-20, 0.1 % BSA in PBS pH 
7.4. Fluorescent intensities of patients’ plasmas were used 
to interpolate antibody concentrations in RU from the 
standard curves.
ELISA was performed as previously described [54]. 
ELISA plates were blocked with 3 % (w/v) skim milk in 
PBS and all antibodies were diluted with 1 % (w/v) skim 
milk in PBS. Each plate included a pool of positive plas-
mas that was diluted two fold from 1/50 to 1/800 to gen-
erate a five point standard curve. The 1/50 dilution of 
pooled positive plasma was assigned an arbitrary value of 
800 relative units (RU). All plasmas were tested at 1/50 
and OD values interpolated from the standard curve for 
that plate. Any plasma that were below the curve were 
assigned the lowest value, any that were above the curve 
were re-tested at two-fold dilutions from 1/50 to 1/400. 
A pool of unexposed donor plasma at the same dilution 
as the test plasmas was included as a negative control in 
every Luminex and ELISA assay.
Statistical analyses
The association between disease severity with age and 
parasitaemia was assessed using a Mann–Whitney U-test 
and with gender using a Fisher’s exact test. RU values for 
individual proteins were compared by Mann–Whitney 
U-test. To compare between patients with severe and 
uncomplicated malaria for antibody responses to pro-
teins belonging to a single domain cassette or PfEMP1 
group, patients were categorized according to whether 
their plasma sample lay above or below the median con-
centration of RU for that antigen: those above or equal 
scoring 1, or 0 if below. To derive a single quantitative 
score for each plasma for all the proteins belonging to a 
single DC or PfEMP1 group, the plasma’s scores for each 
antigen in that DC or group that were determined by 
either Luminex or ELISA were summed.
Any individual plasma with a score of 1 for any pro-
tein within a DC or PfEMP1 group was classified as a 
responder to that DC or PfEMP1. Individual plasma sam-
ples with a combined score of 0 for all proteins within a 
DC or group were classified as non-responders.
Differences in the proportions of severe and uncom-
plicated malaria patients whose plasma responded to 
Shown are the 50 highest-ranked transcripts
a The domains that were expressed for analysis by ELISA are in italics
b Domain annotation is as per [4]: domain subtype_domain (D) position within the PfEMP1 numbered from the most N terminal DBL/CIDR domain_P. falciparum 
isolate name var gene name
c The transcripts are ordered by coverage [reads mapped per kb assembled transcript (rpk)]
Table 1 continued
var Homologsa, b Notes RPKc Contig  
bp
Homology  
bp
E value % Identity
DBLδ1_D7_IT4var22 1454 388 351 6.02E−52 74.1
DBLδ1_D5_igh_var5 1438 281 287 1.07E−40 70.5
DBLβ3_D4_AAQ73927–DBLγ4_
D5_raj116_var8
1428 458 171, 184 8.18E−45, 2.2E−39 83, 79.9
DBLε10_D8_IT4var4 1392 442 138 3.35E−43 87.7
DBLδ1_D4_PFCLINvar28 
(var2csa)
1378 506 138 9.7E−51 91.3
DBLγ8_D7_PFCLINvar76 
(var1csa)
1377 244 200 1.05E−71 92
DBLγ11_D5_DD2var52–DBLδ1_
D4_PFCLINvar36
1351 910 322, 84 3.21E−47, 1.12E−27 73.6, 91.7
DBLα1.6_D2_DD2var22 1320 111 102 1.7E−26 84.3
DBLα0.15_D2_HB3var18 1298 352 306 1.28E−53 77.8
CIDRβ1_D8_IT4var22 1297 431 224 9.97E−69 89.7
CIDRα1.5_D3_ighvar30–DBLβ7_
D7_PFCLINvar69
EPCR binding 1283 2183 (31, 42, 66), 681 (1.06E−3, 3.7E−3, 1.21E−15), 
1.33E−110
(87.1, 90.5, 98.5), 73.6
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a DC or PfEMP1 group were compared by contingency 
tables using Fisher’s exact test. Differences between 
severe and uncomplicated malaria patients in the num-
ber of proteins within a DC or PfEMP1 group to which 
patients responded were compared only for patients who 
responded to at least one protein in the DC or PfEMP1 
group using Mann–Whitney U- tests. This indicated 
differences in the breadth of the response to PfEMP1s 
within that group. The patients that did not respond to 
any protein within the group, i.e. had a score of zero were 
not included to remove any biases associated with large 
frequencies of zero values in non-parametric compari-
sons [57].
Results
Var genes expressed in a Papua New Guinean cerebral 
malaria patient
To identify var sequences transcribed by parasites infect-
ing this patient we used Illumina RNAseq to generate 
65 bp paired-end short reads. Reads that mapped to the 
399 full length var gene sequences available [4] were 
merged with reads that did not map to the P. falciparum 
3D7 strain genome nor Homo sapiens, and the merged 
reads were subjected to two rounds of de novo assembly 
to generate 623 contigs that included 362 contigs with 
homology to var genes. The total length of assembled 
contigs was 200,158  bp, N50 423  bp, maximum contig 
length 4083 bp. The short contig length allowed assembly 
of only a few, full domains. However, the contigs could 
be aligned by BLASTN (E value  <10−5) to individual 
domains from the 399 full-length var genes and orthologs 
of high identity to annotated domains and DC types were 
identified (Table 1).
We compared the percentage of reads from the patient 
that assembled in transcripts with homology to domain 
subtypes with the percentage of total var exon 1 sequence 
in the seven sequenced P. falciparum genomes that each 
domain subtype represented. DBLδ1, NTSB, CIDRβ1, 
NTSA and CIDRα3.1 were all abundant transcripts but 
also constituted a similar proportion of var transcripts 
as the proportion of total var exon1 sequences they con-
stitute in the seven sequenced genomes (Fig.  1). There-
fore, their abundance could represent random var gene 
transcription. Other abundant transcripts (present at 
more than 10  % of the level of total DBLδ1) but which 
were transcribed at more than three times their level of 
representation in the seven sequenced genomes included 
DBLγ6, 4, 9, and 10, DBLδ5, DBLβ6 and 7, CIDRα2.4, 
CIDRb2 and DBLε1 and 6 (Fig. 1).
The abundance of individual transcripts was compared 
using reads mapped per kb of assembled contiguous tran-
script (RPK) (see “Methods” section). The most abundant 
individual transcripts included a diverse range of CIDR 
and DBL domains. The first and eighth most abundant 
transcripts were CIDRα2.4 and CIDRα3.1 sequences that 
could potentially bind CD36 [58] (Table  1). The second 
and third most abundant transcripts had no previous 
associations with severe disease or conserved domain 
cassettes. The fourth and the ninth most abundant were 
DC5 associated DBLδ5 sequences, 12 of the 13 published 
DBLδ5 sequences are present in DC5 genes. The 13th 
and 26th most abundant transcripts were also unique 
DC5 tandem-domain arrangements of DBLγ17-DBLδ5 
and CIDRβ4-DBLβ3, respectively.
The most promising candidates for causing severe 
malaria are the EPCR-binding CIDRα1 domains of DC8 
and DC13 PfEMP1s. The most abundant CIDRα1 capa-
ble of EPCR binding [36] in this patient was a CIDRα1.5-
DBLβ7 contig ranked 50th overall by abundance. All 
described DC8s have a unique DBLα2-CIDRα1.1/1.6/1.8 
tandem domain arrangement [4], but the most abundant 
DBLα2 was ranked 102nd by abundance. Four of the 50 
most abundant transcripts had greatest homology to 
domains found in DC8 PfEMP1s (Table 1). Thus DC8 var 
genes may have been abundantly expressed by the para-
sites infecting this patient however these domains are 
also found at least as frequently in non-DC8 PfEMP1s. 
The DC13 is characterized by the tandem array of a 
DBLα1.7-CIDRα1.4 but neither of these domains were 
abundantly transcribed in this patient.
Var1csa sequences were the 7th, 12th and 45th most 
abundant transcripts; expression of this gene was not 
previously observed to be elevated in severe disease [59] 
and it is ubiquitously transcribed [59, 60], atypically late 
in the cell cycle after transcription of var genes encod-
ing the adhesion phenotype [61, 62]. The 26th, 42nd and 
35th most abundant transcripts were two DBLβ3 and a 
DBLβ5, respectively. DBLβ5 and some DBLβ3 includ-
ing those in DC4 have been shown to bind ICAM-1 [63, 
64]. DBLε10 from var2csa was the 43rd most abundant 
transcript. No other DCs were identified in the 50 most 
abundant transcripts.
Patterns of PfEMP1 antibody reactivity in severe 
and uncomplicated malaria in Papua
Antibody reactivity with PfEMP1 was assessed in plasma 
from 28 patients with severe malaria (median years 29, 
IQR 18.5-34; median P. falciparum parasites/µl 41,220, 
IQR 8260-334,273; 61  % male) and 35 patients with 
uncomplicated malaria (median years 22.5, IQR 18.0-
25.5,; median P. falciparum parasites/µl 27,680, IQR 
16,800-52,800; 54  % male). Patients with severe malaria 
tended to be older than those with uncomplicated 
malaria (p  =  0.0599), but there was no significant dif-
ference in P. falciparum density (p = 0.7288) and gender 
(p = 0.7981). Twenty-three patients with severe malaria 
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had a single diagnostic criterion (WHO) [48], includ-
ing five with cerebral malaria, six with jaundice, eight 
with hyperparasitaemia, three with prostration, and one 
with acute renal failure. Five patients had two or more 
manifestations of severe malaria: one patient with jaun-
dice and prostration, one with acute renal failure and 
acute respiratory distress syndrome, one with jaundice 
and hyperparasitaemia, and two with jaundice and acute 
renal failure.
To examine the reactivity of Papuan patient plasma 
with different PfEMP1 groups and DCs previously asso-
ciated with severe or uncomplicated disease we tested 10 
PfEMP1 DCs and the non-PfEMP1 proteins GLURP and 
MSP3 by a Luminex multiplexed bead assay; and twelve 
recombinant, partial PfEMP1 domains by ELISA. The 
proteins tested included groupings previously associ-
ated with severe disease (DC8, DC13, DC5, group A and 
group B) (Fig.  2). Individual datapoints for all plasmas 
and all antigens tested are presented in Additional file 1.
The DC domain constructs used in the Luminex 
assay were derived from the 3D7, ItG and HB3 isolates. 
Seven of the proteins used for ELISA were derived from 
sequences transcribed in the PNG cerebral malaria 
patient described above and included abundantly tran-
scribed (by RPK) representatives of DC5 DBLβ7, DC5 
DBLδ5, DC8 DBLγ6 and DBLγ10 (Table  1; Fig.  2b and 
see “Methods” section for details). These domain sub-
types were all transcribed at more than threefold their 
level of representation in the seven sequenced genomes 
(Fig.  1). The most abundantly transcribed representa-
tive of the conserved NTS-DBLα arrangement was also 
included as well as a less abundant DBLd1 transcript 
(protein 7) (Table  1; Fig.  2b). By Luminex assay, levels 
of antibodies to MSP3 but not GLURP were higher in 
plasma from patients with uncomplicated malaria than 
in severe malaria, (Fig.  2a) (median MSP3 22 versus 11 
RU, respectively, p  =  0.055). The MSP3 data suggests 
that patients with uncomplicated malaria may have had 
more prior exposure to P. falciparum infection than the 
patients with severe malaria.
In the Luminex assay, patients with uncomplicated 
malaria generally had higher levels of antibody to indi-
vidual PfEMP1s than patients with severe disease, the 
greatest difference being in a DC16 PfEMP1 (p = 0.0095) 
(Fig.  2a). Interestingly DC16 are group A PfEMP1s that 
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have been shown not to be associated with severe disease 
[38]. For four proteins, there was no significant differ-
ence (all p > 0.054) in antibody response between plasma 
from patients with severe and uncomplicated malaria. 
These proteins included three severe malaria-associated 
PfEMP1s, two DC5, and one DC8 (Fig. 2a).
In the ELISA, patients with uncomplicated malaria had 
significantly higher levels of antibody than patients with 
severe malaria to two group C PfEMP1s that were from 
lab isolates and a single group B DBLγ from the cerebral 
malaria patient (Fig. 2b; p < 0.05). A non-significant trend 
in the same direction (p < 0.10) was observed for a single 
DC5 and a single DC8.
The combined results for the ELISA and the Luminex 
assays revealed that a greater proportion of the patients 
with uncomplicated malaria than with severe malaria 
had antibodies to group C PfEMP1s (p =  0.004) and to 
PfEMP1s that were not DC5, nor 8, nor 13 (p =  0.008) 
(Fig.  3a). While the proportion of plasma reactive with 
severe malaria-associated proteins was higher in individ-
uals with uncomplicated compared to severe malaria, the 
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magnitude of the difference was smaller and not statisti-
cally significant (all p > 0.194). It is possible that analysing 
larger numbers of proteins in these groupings on a single 
platform may have detected differences.
Amongst patients with an antibody response to at least 
one protein of a cassette or group, plasma from patients 
with uncomplicated malaria recognized more PfEMP1s 
overall, and more group A and group B PfEMP1s than 
did plasma from patients with severe malaria (p = 0.031, 
p  =  0.044 and p  =  0.014, respectively, Fig.  3b). Thus 
although similar proportions of patients with severe and 
uncomplicated malaria had been exposed to at least one 
group A or group B PfEMP1 (Fig.  3a), the breadth of 
responses to the group A and group B PfEMP1s tested 
was lower in patients with severe malaria.
Discussion
Sequencing the transcriptome of parasites causing CM 
in a single patient enabled assembly of a snapshot of the 
transcribed var repertoire in human malaria. Although 
entire genes could not be assembled, advances in the 
phylogenetics of var sequences [4] allowed the var con-
tigs to be separated into useful classifications. Previ-
ous studies that implicated parasites expressing group 
A PfEMP1s [20, 23–25] and group B PfEMP1s [26] in 
severe disease provided no, or minimal, sequence data 
and were essentially restricted to classifying sequences to 
the groups defined by the var gene upstream sequences 
or by sequencing short DBLα tags.
The RNAseq of parasites causing CM in this PNG 
patient was consistent with previous studies of var 
genes in pathogenesis and abundantly expressed var 
genes identified included DC5 and possibly DC8, the 
DBLβ3 domain subtype and individual domains includ-
ing CIDRα1.5 and DBLβ3. Recombinant proteins derived 
from the latter two domain subtypes have been shown 
to bind EPCR and ICAM-1 respectively [30, 36]. Other 
abundantly transcribed domain subtypes had not previ-
ously been identified in severe malaria. This limited study 
of a single patient indicates that RNAseq will be useful 
for identifying quantitative differences between tran-
scribed var genes in severe disease in future studies.
The diversity of the transcribed var repertoire was con-
sistent with a previous report of cerebral malaria in Africa 
[65]. However, 45 % of the reads that assembled into var 
transcripts were in the 20 most abundant var contigs that 
between them represented 27 domains. Thus the quanti-
tative nature of RNAseq revealed a hierarchy of var tran-
script abundance in this patient’s peripheral blood that 
would be difficult to detect using the non-quantitative, 
nested RT-PCR approaches available to this previous 
study [65]. This suggests that the dominant var transcripts 
expressed by parasites causing cerebral malaria in a single 
patient are probably restricted in number.
Patients with uncomplicated malaria more commonly 
had antibodies to PfEMP1s that were from Group C or 
were not from DC5 nor DC8 nor DC13 than patients 
with severe malaria (Fig. 3a). In contrast, similar propor-
tions of patients with severe and uncomplicated malaria 
had developed antibodies to the severe malaria associated 
PfEMP1s (group A and B, DC5, 8 and 13) (Fig. 3a), but 
the breadth of the response to group A and B PfEMP1s 
was greater in patients with uncomplicated than severe 
disease (Fig. 3b). Thus susceptibility to severe disease was 
associated with recognition of a narrower range of group 
A and B PfEMP1s and to an overall lack of antibodies to 
group C PfEMP1s and to PfEMP1s that were not DC5 
nor DC8 nor DC13.
Overall, the serology findings in this Papuan adult 
population are consistent with existing models of infec-
tion in African children where parasites expressing severe 
malaria-associated group A and B PfEMP1s infect naive 
individuals and elicit antibodies [20, 66]. Susceptible, 
semi-immune individuals have antibody to some group 
A and B PfEMP1s [27], but protective immunity corre-
lates with acquisition of antibodies recognizing a broader 
range of PfEMP1s [5–8]. Parasites expressing uncompli-
cated disease associated group C PfEMP1s, or PfEMP1s 
that were not DC5, 8 nor 13, would only dominate infec-
tions after parasites expressing severe disease associated 
PfEMP1s were controlled by acquisition of a broad anti-
body response. The alternative explanation is that group C 
PfEMP1s and PfEMP1s that were not DC5, 8 nor 13 were 
abundantly expressed by parasites causing acute, severe 
malaria but had not yet elicited antibodies. Although this 
cannot be excluded it is inconsistent with previous studies 
of var gene expression in both Africa and PNG [20–26].
Conclusion
In Papuan adults severe malaria is associated with a lack 
of antibodies to non-DC5 and 8 and group C PfEMP1s 
in general, and with antibodies to a narrower repertoire 
of group A and group B PfEMP1s than in patients with 
uncomplicated malaria. These findings from Papua are 
consistent with reports from Africa of elevated group A 
and B var gene expression in severe disease [20, 23–26] 
and of earlier development of antibodies to group A 
PfEMP1s in children [27, 29]. This study has also estab-
lished the feasibility of performing RNAseq on patient 
isolates to identify expressed var gene sequences.
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